Cabot (CBT) to Release Earnings on Monday

Cabot (NYSE:CBT) is expected to be posting its Q4 2025 results after the market closes on Monday, November 3rd. Analysts expect Cabot to post earnings of $1.74 per share and revenue of $967.0170 million for the quarter. Cabot has set its FY 2025 guidance at 7.150-7.500 EPS.Individuals are encouraged to explore the company’s upcoming Q4 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:00 AM ET.

Cabot (NYSE:CBT) last issued its earnings results on Monday, August 4th. The specialty chemicals company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.80 by $0.10. Cabot had a return on equity of 25.68% and a net margin of 11.14%.The business had revenue of $923.00 million for the quarter, compared to analyst estimates of $957.29 million. On average, analysts expect Cabot to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Cabot Price Performance

Shares of NYSE CBT opened at $67.46 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 2.13. Cabot has a fifty-two week low of $65.59 and a fifty-two week high of $117.46. The firm has a market capitalization of $3.59 billion, a PE ratio of 8.82 and a beta of 0.88. The stock’s 50-day simple moving average is $75.45 and its 200-day simple moving average is $76.12.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. UBS Group set a $82.00 target price on Cabot and gave the stock a “neutral” rating in a research report on Tuesday, August 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Cabot in a research report on Wednesday, October 8th. Finally, Mizuho cut their target price on Cabot from $90.00 to $88.00 and set an “outperform” rating on the stock in a research report on Friday, October 3rd. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $85.00.

Insider Transactions at Cabot

In related news, CEO Sean D. Keohane sold 114,436 shares of the firm’s stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $79.28, for a total transaction of $9,072,486.08. Following the transaction, the chief executive officer owned 361,518 shares in the company, valued at $28,661,147.04. This trade represents a 24.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 3.03% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of CBT. Geneos Wealth Management Inc. increased its holdings in shares of Cabot by 409.0% in the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock valued at $38,000 after purchasing an additional 364 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Cabot by 344.3% in the second quarter. EverSource Wealth Advisors LLC now owns 813 shares of the specialty chemicals company’s stock valued at $61,000 after purchasing an additional 630 shares during the period. NewEdge Advisors LLC increased its holdings in shares of Cabot by 2,559.5% in the first quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock valued at $82,000 after purchasing an additional 947 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Cabot in the first quarter valued at approximately $96,000. Finally, Gamco Investors INC. ET AL acquired a new position in shares of Cabot in the second quarter valued at approximately $252,000. 93.18% of the stock is currently owned by hedge funds and other institutional investors.

Cabot Company Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.